Mohamed Sikkander Abdul Razak: A New Strategy to Reprogram Cancer Cells Instead of Killing Them
Mohamed Sikkander Abdul Razak, Professor at GKM College of Engineering Technology, shared a post on LinkedIn:
“Scientists at KAIST have identified three genetic switches – MYB, HDAC2, and FOXA2 – that keep cancer cells, specifically colon cancer cells, in a malignant state.
By inhibiting these genes, they’ve successfully reprogrammed cancer cells to behave like normal, healthy cells.
This breakthrough could lead to a new approach in cancer treatment, focusing on reprogramming rather than killing cancer cells.
Some key points about this research:
- MYB: Often overactive in colon and blood cancers, promoting growth and preventing cell maturation.
- HDAC2: Helps cancer cells survive by shutting down protective genes.
- FOXA2: Plays complex roles in cell development and cancer growth.
The researchers used a computational model called BENEIN to identify these genetic switches and achieved promising results in lab and animal studies.
This research could lead to:
- Targeted therapies: Developing treatments that reprogram cancer cells to behave normally, reducing harm to healthy cells.
- Personalized medicine: Identifying specific genetic switches in individual patients’ cancers to tailor treatments.
- Combination therapies: Using reprogramming approaches alongside existing treatments like chemotherapy.
- Cancer prevention: Potentially preventing cancer progression in high-risk individuals.
The BENEIN model could also be applied to other cancer types, making it a valuable tool.
Some challenges:
- Specificity: Ensuring treatments target cancer cells only, avoiding off-target effects.
- Delivery: Effectively delivering therapies to all cancer cells, especially in solid tumors.
- Resistance: Cancer cells might develop resistance to reprogramming.
- Long-term efficacy: Ensuring reprogrammed cells remain healthy long-term.
- Complexity: Cancer involves multiple pathways; targeting three switches might not be enough.
Translating lab findings to human treatments will require careful clinical trials.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 10:32Natalie Arnold: The Lp(a) Puzzle – Why Lower Levels May Not Tell the Whole Story
-
Nov 9, 2026, 10:22ISBT Opens Applications for the I TRY IT Programme 2027
-
Nov 9, 2026, 10:08Ibrahim Mansoor: Rare Tests, Common Diseases – Rethinking Autoimmune Diagnostics
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services